Virtual Event Gathers Over 140 Leading
Companies for Presentations and Fireside Chats, Hosted by
Oppenheimer's Healthcare Equity Research Analysts
Conference Combines In-Depth Discussions
Between Executives and Investors With Oppenheimer's Expertise in
Healthcare Research and Investment Banking
NEW
YORK, Feb. 13, 2024 /PRNewswire/ -- Oppenheimer
& Co. Inc. (Oppenheimer) — a leading investment bank, wealth
manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY)
— today announced that its 34th Annual Healthcare
Life Sciences Conference will be held February 13-14. The
virtual event gathers more than 140 public and private healthcare
companies, representing more than $230
billion in market capitalization.
Michael Margolis, R.Ph.,
Oppenheimer's Co-Head of Healthcare and Head of Healthcare Life
Sciences Investment Banking, said, "Breakthroughs by innovative
companies in the healthcare and life sciences space are creating
exciting new opportunities for investors, as signs of more
favorable conditions have begun to emerge in the macroeconomic
landscape. This makes it an ideal time for Oppenheimer to once
again bring together executives and investors for meaningful
conversations across an array of sectors."
In a demonstration of Oppenheimer's continued momentum in the
healthcare sectors, the conference comes after Oppenheimer's
Healthcare Investment Banking team has raised over $8.8 billion in 177 bookrun transactions since
March 2017.
The conference will feature presentations and fireside chats,
hosted by Oppenheimer's healthcare equity research analysts, as
well as the opportunity for investors to meet with company
managements in 1on1 and small group meetings. Oppenheimer's Life
Science analysts include:
- Joel Sendek, Managing Director,
Head of Life Sciences Equity Research
- Matt Biegler, Executive Director and Senior Analyst,
Biotechnology
- François Brisebois, Managing Director and Senior Analyst,
Biotechnology
- Leland Gershell, M.D., Ph.D., Managing Director and Senior
Analyst, Biotechnology
- Jeff Jones, Ph.D., Managing Director and Senior Analyst,
Biotechnology
- Justin Kim, Executive Director
and Senior Analyst, Biotechnology
- Jay Olson, CFA, Managing
Director and Senior Analyst, Biotechnology
- Hartaj Singh, Managing Director and Senior Analyst,
Biotechnology
Erica L. Moffett, Associate
Director of Research and Head of Corporate Access at Oppenheimer,
said, "Healthcare and life sciences companies can make highly
important contributions to society when they have direct access to
investors who are searching for promising market strategies. We are
thrilled to welcome the companies and investors who will make our
34th Annual Healthcare Life Sciences Conference yet
another successful and thought-provoking Oppenheimer event."
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc.
(Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc.
(OPY on the New York Stock Exchange), and its affiliates provide a
full range of wealth management, securities brokerage and
investment banking services to high net-worth individuals,
families, corporate executives, local governments, businesses and
institutions.
Media Contact:
Joseph
Kuo / Michael Dugan
Haven Tower Group LLC
424 317 4851 or 424 317 4852
jkuo@haventower.com or
mdugan@haventower.com
View original
content:https://www.prnewswire.com/news-releases/oppenheimer--co-inc-announces-34th-annual-healthcare-life-sciences-conference-302060240.html
SOURCE Oppenheimer & Co. Inc.